Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients

    NEXT STORY
    CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
    PREV STORY
    Tauriga Sciences Inc. and Aegea Biotechnologies Inc. Enter into Collaboration Agreement to Develop a Rapid, Multiplexed Novel Coronavirus (COVID-19) Test Designed to Exhibit Superior Performance
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aptinyx Reports Third Quarter 2019 Financial Results and Highlights

    author_avatar
    NASDAQ Market News

    Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    author_avatar
    NASDAQ Market News

    PreCheck Health Services, Inc. appoints Dr. Mitch Ghen as its Chief Science Officer

    author_avatar
    NASDAQ Market News